, Volume 56, Issue 3, pp 279-285
Date: 07 Jan 2013

Incorporation of azide sugar analogue decreases tumorigenic potential of breast cancer cells by reducing cancer stem cell population

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


The azido sugar, GalNAz, was successfully used for imaging and perturbing protein glycosylation in triple-negative breast cancer cell line, MDA-MB-231. After the incorporation of GalNAz in the triple-negative breast cancer cell line, the tumorigenicity of these cells was decreased. Results from gene analysis and drug treatment suggest that the tumorigenicity decrease may be attributed to the reduction of cancer stem cell population. Possible mechanisms of GalNAz induced cancer stem cells (CSCs) proportion change are discussed.